托珠单抗对重症或危重型2019冠状病毒病患者15天临床结局的影响:随机对照试验
该随机、开放标签试验在巴西9家医院纳入129例确诊COVID-19、接受补充氧疗或机械通气且至少两项血清生物标志物异常的成人患者。托珠单抗组(单次静脉输注8 mg/kg联合标准治疗,n=65)与单纯标准治疗组(n=64)比较,主要终点15天临床状态(七级序数量表)因比例优势假设不满足而按死亡或机械通气的复合终点分析。结果显示托珠单抗组18/65(28%) vs 标准治疗组13/64(20%)在第15天接受机械通气或死亡(OR 1.54,95%CI 0.66-3.66;P=0.32);第15天死亡在托珠单抗组为11例(17%),标准治疗组为2例(3%)(OR 6.42,95%CI 1.59-43.2)。作者结论认为托珠单抗联合标准治疗不优于单纯标准治疗,且可能增加死亡率。
要点
- 在重症或危重型COVID-19成人患者中,托珠单抗单次静脉输注8 mg/kg联合标准治疗,15天死亡或机械通气复合终点为28%(18/65) vs 标准治疗20%(13/64),OR 1.54(95%CI 0.66-3.66;P=0.32),未达统计学显著。
- 托珠单抗组15天死亡11例(17%) vs 标准治疗组2例(3%),OR 6.42(95%CI 1.59-43.2),托珠单抗可能增加死亡率。
- 数据监测委员会因托珠单抗组15天死亡增加而建议提前终止试验,最终仅纳入129例患者。
- 托珠单抗组不良事件29/67(43%) vs 未接受托珠单抗组21/62(34%)。
- 作者结论:在重症或危重型COVID-19患者中,托珠单抗联合标准治疗不优于单纯标准治疗,且可能增加死亡率。
适用人群与场景
- 确诊COVID-19的成人患者,正在接受补充氧疗或机械通气,且至少两项血清生物标志物(C反应蛋白、D二聚体、乳酸脱氢酶或铁蛋白)水平异常。
诊断标准与关键阈值
- 至少两项血清生物标志物(C反应蛋白、D二聚体、乳酸脱氢酶或铁蛋白)水平异常。
处置流程与药物剂量
- 托珠单抗单次静脉输注8 mg/kg联合标准治疗。
- 对照组仅接受标准治疗;标准治疗组中有2例接受了托珠单抗。
研究设计与关键结果
- 随机、开放标签试验,在巴西9家医院进行,2020年5月8日至7月17日纳入129例患者(平均年龄57岁,标准差14;68%为男性),全部完成随访。
- 主要终点为15天时七级序数量表临床状态,因比例优势假设不满足,按死亡或机械通气的复合终点分析:托珠单抗组18/65(28%) vs 标准治疗组13/64(20%),OR 1.54(95%CI 0.66-3.66;P=0.32)。
- 15天死亡:托珠单抗组11例(17%) vs 标准治疗组2例(3%),OR 6.42(95%CI 1.59-43.2)。
- 不良事件:接受托珠单抗者29/67(43%) vs 未接受托珠单抗者21/62(34%)。
- 数据监测委员会因托珠单抗组15天死亡增加而建议提前终止试验,最终纳入129例。
证据类型、等级与局限
- 证据类型:随机、开放标签试验。
- 局限:数据监测委员会因托珠单抗组15天死亡增加而建议提前终止试验,最终仅纳入129例患者。
对床旁实践的改变
- 作者结论认为,在重症或危重型COVID-19患者中,托珠单抗联合标准治疗在改善15天临床结局方面不优于单纯标准治疗,且可能增加死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19).
DESIGN: Randomised, open label trial.
SETTING: Nine hospitals in Brazil, 8 May to 17 July 2020.
PARTICIPANTS: Adults with confirmed covid-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two serum biomarkers (C reactive protein, D dimer, lactate dehydrogenase, or ferritin). The data monitoring committee recommended stopping the trial early, after 129 patients had been enrolled, because of an increased number of deaths at 15 days in the tocilizumab group.
INTERVENTIONS: Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65) versus standard care alone (n=64).
MAIN OUTCOME MEASURE: The primary outcome, clinical status measured at 15 days using a seven level ordinal scale, was analysed as a composite of death or mechanical ventilation because the assumption of odds proportionality was not met.
RESULTS: A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed follow-up. All patients in the tocilizumab group and two in the standard care group received tocilizumab. 18 of 65 (28%) patients in the tocilizumab group and 13 of 64 (20%) in the standard care group were receiving mechanical ventilation or died at day 15 (odds ratio 1.54, 95% confidence interval 0.66 to 3.66; P=0.32). Death at 15 days occurred in 11 (17%) patients in the tocilizumab group compared with 2 (3%) in the standard care group (odds ratio 6.42, 95% confidence interval 1.59 to 43.2). Adverse events were reported in 29 of 67 (43%) patients who received tocilizumab and 21 of 62 (34%) who did not receive tocilizumab.
CONCLUSIONS: In patients with severe or critical covid-19, tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04403685.
参考来源
- Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021. PMID: 33472855. doi:10.1136/bmj.n84
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。